ARTICLE | Company News
Sprout appealing FDA complete response for flibanserin
December 12, 2013 3:11 AM UTC
Sprout Pharmaceuticals Inc. (Raleigh, N.C.) is appealing a complete response letter from FDA for flibanserin to treat hypoactive sexual desire disorder (HSDD). Rhe company received the complete response letter for the resubmitted NDA in September. Sprout said it expects a decision on the appeal in 1Q14. ...